The DSMC IMO, is quite certain that we will probably achieve Statistical Significance. In fact, they may have done some exploratory math, keeping the same ratio of placebo deaths to leronlimab deaths, but extending the total number of patients to 300 (or maybe 293?) and that gave an amazing p value, Statistical Significance.
Why do another Interim analysis at 293? Answer: to get Leronlimab to the market sooner with full unrestricted approval.
Why extend the 28 day mortality to 42? Answer: because they know that some placebo s/c do die after 28 days AND, this change also would increase the probability even more to assure our great p value.